CG
BMRN icon

Carmignac Gestion’s BioMarin Pharmaceuticals BMRN Stock Holding History

Carmignac Gestion’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$8.93K – 145
2023
Q3 		$8.93K Sell
100
-1,081,856
-100% -$96.3M ﹤0.01% 144
2023
Q2 		$93.8M Buy
1,081,956
+37,585
+4% +$3.54M 1.62% 21
2023
Q1 		$102M Buy
1,044,371
+175,759
+20% +$18.2M 1.69% 24
2022
Q4 		$89.9M Buy
+868,612
New +$81.5M 1.62% 22

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Carmignac Gestion's BMRN Position: Q4 2023 in Review

Carmignac Gestion sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 100 shares — an estimated $8.93K sold.

Carmignac Gestion first reported a position in BMRN in Q4 2022 and held it in 4 quarters. The position peaked at $102M in Q1 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Carmignac Gestion reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Carmignac Gestion sold 100 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $8.93K.
  • Carmignac Gestion first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Carmignac Gestion's BioMarin Pharmaceuticals position peaked at $102M in Q1 2023.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Carmignac Gestion's 13F filing for Q4 2023, filed 13 Feb 2024.